0.33(0.39%) Volume: 338,171 4:00PM EDT| Market Cap : 4.86 B | Enterprise Value : 4.43 B | P/E (TTM) : | P/B : 10.98 |
|---|
NAS:AGIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:AGIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | No Debt |
AGIO's Cash-to-Debt is ranked higher than
77% of the 1056 Companies in the Global Biotechnology industry. ( Industry Median: 73.06 vs. AGIO: No Debt ) Ranked among companies with meaningful Cash-to-Debt only. |
AGIO'
s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt Current: No Debt |
| Equity-to-Asset | 0.61 |
AGIO's Equity-to-Asset is ranked lower than
60% of the 770 Companies in the Global Biotechnology industry. ( Industry Median: 0.68 vs. AGIO: 0.61 ) Ranked among companies with meaningful Equity-to-Asset only. |
AGIO'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32 Med: 0.61 Max: 0.86 Current: 0.61 |
| Interest Coverage | No Debt |
AGIO's Interest Coverage is ranked higher than
70% of the 521 Companies in the Global Biotechnology industry. ( Industry Median: 10000.00 vs. AGIO: No Debt ) Ranked among companies with meaningful Interest Coverage only. |
AGIO'
s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt Current: No Debt |
| Piotroski F-Score: 2 |
|
| Altman Z-Score: 9.74 |
|
| Beneish M-Score: -1.97 |
|
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | -745.84 |
AGIO's Operating Margin % is ranked lower than
73% of the 800 Companies in the Global Biotechnology industry. ( Industry Median: -98.02 vs. AGIO: -745.84 ) Ranked among companies with meaningful Operating Margin % only. |
AGIO'
s Operating Margin % Range Over the Past 10 Years
Min: -745.84 Med: -152.2 Max: -76.16 Current: -745.84 |
| Net Margin % | -731.60 |
AGIO's Net Margin % is ranked lower than
74% of the 800 Companies in the Global Biotechnology industry. ( Industry Median: -88.19 vs. AGIO: -731.60 ) Ranked among companies with meaningful Net Margin % only. |
AGIO'
s Net Margin % Range Over the Past 10 Years
Min: -731.6 Med: -154.25 Max: -80.07 Current: -731.6 |
| ROE % | -78.66 |
AGIO's ROE % is ranked lower than
68% of the 969 Companies in the Global Biotechnology industry. ( Industry Median: -40.23 vs. AGIO: -78.66 ) Ranked among companies with meaningful ROE % only. |
AGIO'
s ROE % Range Over the Past 10 Years
Min: -85.73 Med: -49.69 Max: -19.25 Current: -78.66 |
| ROA % | -48.58 |
AGIO's ROA % is ranked lower than
60% of the 1062 Companies in the Global Biotechnology industry. ( Industry Median: -32.55 vs. AGIO: -48.58 ) Ranked among companies with meaningful ROA % only. |
AGIO'
s ROA % Range Over the Past 10 Years
Min: -51.02 Med: -23.3 Max: -12.13 Current: -48.58 |
| ROC (Joel Greenblatt) % | -1307.26 |
AGIO's ROC (Joel Greenblatt) % is ranked lower than
64% of the 1021 Companies in the Global Biotechnology industry. ( Industry Median: -430.94 vs. AGIO: -1307.26 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
AGIO'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1307.26 Med: -827.83 Max: -516.17 Current: -1307.26 |
| 3-Year Revenue Growth Rate | -21.90 |
AGIO's 3-Year Revenue Growth Rate is ranked lower than
74% of the 604 Companies in the Global Biotechnology industry. ( Industry Median: 4.00 vs. AGIO: -21.90 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
AGIO'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.5 Med: -9.7 Max: 13.3 Current: -21.9 |
| 3-Year EBITDA Growth Rate | -62.70 |
AGIO's 3-Year EBITDA Growth Rate is ranked lower than
91% of the 722 Companies in the Global Biotechnology industry. ( Industry Median: 3.10 vs. AGIO: -62.70 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
AGIO'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -62.7 Med: -37.75 Max: 33.2 Current: -62.7 |
| 3-Year EPS without NRI Growth Rate | -61.90 |
AGIO's 3-Year EPS without NRI Growth Rate is ranked lower than
92% of the 704 Companies in the Global Biotechnology industry. ( Industry Median: 4.20 vs. AGIO: -61.90 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
AGIO'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -61.9 Med: -30.1 Max: 43.7 Current: -61.9 |
| George Soros 3,900 sh (New) | Vanguard Health Care Fund 3,581,634 sh (unchged) | Columbia Wanger 610,086 sh (-4.12%) Steven Cohen 62,500 sh (-37.50%) |
| Steven Cohen 203,000 sh (+224.80%) Columbia Wanger 768,942 sh (+26.04%) Vanguard Health Care Fund 3,874,924 sh (+8.19%) | George Soros Sold Out |
| George Soros 3,500 sh (New) Columbia Wanger 889,142 sh (+15.63%) | Vanguard Health Care Fund 3,874,924 sh (unchged) | Steven Cohen 129,640 sh (-36.14%) |
| Vanguard Health Care Fund 3,874,924 sh (unchged) | George Soros Sold Out Columbia Wanger 760,116 sh (-14.51%) Steven Cohen 91,500 sh (-29.42%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Trades | Impact to Portfolio | Price Range * (?) | Current Price | Change from Average | Current Shares | |
|---|---|---|---|---|---|---|---|---|
| George Soros | 2017-12-31 | Sold Out | 0.01% | $52.12 - $72.33 | $ 84.38 | 34% | 0 |  |
| George Soros | 2017-09-30 | New Buy | 0.01% | $52.18 - $67.12 | $ 84.38 | 41% | 3,500 | |
| Vanguard Health Care Fund | 2017-06-30 | Add 8.19% | 0.03% | $46.67 - $59.18 | $ 84.38 | 65% | 3,874,924 | |
| George Soros | 2017-06-30 | Sold Out | 0.01% | $46.67 - $59.18 | $ 84.38 | 65% | 0 | |
More recent guru trades are included for Premium Members only!! More recent guru trades are included for USA Subscribe Members only!!
What is Peter Lynch Charts )| Industry: | Biotechnology » Biotechnology NAICS: 325412 SIC: 2834 | |
|---|---|---|
| Compare: | OSTO:SOBI, NAS:UTHR, SZSE:000661, NAS:AVXS, NAS:SRPT, NAS:BPMC, XKRX:128940, SZSE:002007, BOM:532523, HKSE:01548, XBRU:ABLX, HKSE:01530, SHSE:600201, NAS:TECH, NAS:FGEN, SZSE:300347, NAS:AAAP, LSE:BTG, LSE:ABC, TSE:4587 » details | |
| Traded in other countries: | 8AP.Germany, | |
| Headquarter Location: | USA |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PB Ratio | 10.98 |
AGIO's PB Ratio is ranked lower than
80% of the 954 Companies in the Global Biotechnology industry. ( Industry Median: 4.51 vs. AGIO: 10.98 ) Ranked among companies with meaningful PB Ratio only. |
AGIO'
s PB Ratio Range Over the Past 10 Years
Min: 3.8 Med: 7.11 Max: 16.81 Current: 10.98 |
| PS Ratio | 91.03 |
AGIO's PS Ratio is ranked lower than
82% of the 733 Companies in the Global Biotechnology industry. ( Industry Median: 9999.00 vs. AGIO: 91.03 ) Ranked among companies with meaningful PS Ratio only. |
AGIO'
s PS Ratio Range Over the Past 10 Years
Min: 7.11 Med: 39.64 Max: 94.21 Current: 91.03 |
| EV-to-EBIT | -13.82 |
AGIO's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies in the Global Biotechnology industry. ( Industry Median: 24.43 vs. AGIO: -13.82 ) Ranked among companies with meaningful EV-to-EBIT only. |
AGIO'
s EV-to-EBIT Range Over the Past 10 Years
Min: -89.2 Med: -11.6 Max: -4.5 Current: -13.82 |
| EV-to-EBITDA | -14.14 |
AGIO's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies in the Global Biotechnology industry. ( Industry Median: 21.70 vs. AGIO: -14.14 ) Ranked among companies with meaningful EV-to-EBITDA only. |
AGIO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -91.9 Med: -12 Max: -4.6 Current: -14.14 |
| EV-to-Revenue | 103.05 |
AGIO's EV-to-Revenue is ranked lower than
79% of the 777 Companies in the Global Biotechnology industry. ( Industry Median: 13.46 vs. AGIO: 103.05 ) Ranked among companies with meaningful EV-to-Revenue only. |
AGIO'
s EV-to-Revenue Range Over the Past 10 Years
Min: 8.1 Med: 35.15 Max: 89.2 Current: 103.05 |
| Current Ratio | 4.69 |
AGIO's Current Ratio is ranked higher than
53% of the 1035 Companies in the Global Biotechnology industry. ( Industry Median: 4.21 vs. AGIO: 4.69 ) Ranked among companies with meaningful Current Ratio only. |
AGIO'
s Current Ratio Range Over the Past 10 Years
Min: 3.71 Med: 4.69 Max: 6.38 Current: 4.69 |
| Quick Ratio | 4.69 |
AGIO's Quick Ratio is ranked higher than
56% of the 1035 Companies in the Global Biotechnology industry. ( Industry Median: 3.92 vs. AGIO: 4.69 ) Ranked among companies with meaningful Quick Ratio only. |
AGIO'
s Quick Ratio Range Over the Past 10 Years
Min: 3.71 Med: 4.69 Max: 6.38 Current: 4.69 |
| Days Sales Outstanding | 7.29 |
AGIO's Days Sales Outstanding is ranked higher than
77% of the 656 Companies in the Global Biotechnology industry. ( Industry Median: 64.11 vs. AGIO: 7.29 ) Ranked among companies with meaningful Days Sales Outstanding only. |
AGIO'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.29 Med: 16.93 Max: 20.83 Current: 7.29 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.60 |
AGIO's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 768 Companies in the Global Biotechnology industry. ( Industry Median: -13.20 vs. AGIO: -9.60 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
AGIO'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -130.9 Med: -14.15 Max: -9.6 Current: -9.6 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Net-Cash | 22.26 |
AGIO's Price-to-Net-Cash is ranked lower than
79% of the 568 Companies in the Global Biotechnology industry. ( Industry Median: 8.85 vs. AGIO: 22.26 ) Ranked among companies with meaningful Price-to-Net-Cash only. |
AGIO'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.28 Med: 10.11 Max: 22.88 Current: 22.26 |
| Price-to-Net-Current-Asset-Value | 19.95 |
AGIO's Price-to-Net-Current-Asset-Value is ranked lower than
82% of the 695 Companies in the Global Biotechnology industry. ( Industry Median: 7.88 vs. AGIO: 19.95 ) Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only. |
AGIO'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.89 Med: 9.33 Max: 20.5 Current: 19.95 |
| Price-to-Tangible-Book | 10.97 |
AGIO's Price-to-Tangible-Book is ranked lower than
72% of the 874 Companies in the Global Biotechnology industry. ( Industry Median: 5.88 vs. AGIO: 10.97 ) Ranked among companies with meaningful Price-to-Tangible-Book only. |
AGIO'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.91 Med: 7.09 Max: 11.28 Current: 10.97 |
| Price-to-Median-PS-Value | 2.30 |
AGIO's Price-to-Median-PS-Value is ranked lower than
85% of the 614 Companies in the Global Biotechnology industry. ( Industry Median: 1.00 vs. AGIO: 2.30 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
AGIO'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.25 Med: 1.03 Max: 2.36 Current: 2.3 |
| Earnings Yield (Greenblatt) % | -7.25 |
AGIO's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 1060 Companies in the Global Biotechnology industry. ( Industry Median: -6.86 vs. AGIO: -7.25 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
AGIO'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -22.4 Med: -8.6 Max: -1.1 Current: -7.25 |
| Revenue (TTM) (Mil) $ | 43.01 |
|---|---|
| EPS (TTM) $ | -6.74 |
| Beta | 2.69 |
| Volatility | 46.74% |
| 52-Week Range $ | 45.11 - 89.33 |
| Shares Outstanding (Mil) | 57.56 |
| Dec18 | Dec19 | Dec20 | |
|---|---|---|---|
| Revenue (Mil $) | 92 | 370 | 678 |
| EBIT (Mil $) | -370 | -140 | -6 |
| EBITDA (Mil $) | -349 | -274 | -73 |
| EPS ($) | -6.11 | -1.61 | 1.43 |
| EPS without NRI ($) | -6.11 | -1.61 | 1.43 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | ||
| Dividends per Share ($) | |||
|
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP